Friday, November 27, 2020

Abbott Laboratories [ABT] is 6.56% higher this YTD. Is it still time to buy?

Must read

NVIDIA (NVDA) Stock Lost After Q3 Results, Record Revenues Did Not Help

The graphics chip (GPU) manufacturer NVIDIA Corp. (NVDA) issued its report for the third quarter of the fiscal year 2021 after the close of...

Spirit Airline (SAVE), United Airline (UAL) Stock Surged, Quicker Recovery Will Be The Key To Growth

Good news on the efficacy of COVID-19 vaccines confirms stocks from airlines that have been among the most impacted by social activity constraints. Optimism...

U.S. Indices Started The Week Well, Oil Sector Also Gained

On the back of growing market operation and the results of testing another vaccine, our indexes rose Key-U.S. indices closed in the green zone on...

Unity Software (U) Stock Added 7% Last Week After Positive Quarterly Results

The stock of the game engine developer Unity Software Inc. (U) rose 5.58 percent on Friday to conclude the week at $122.80. An optimistic report...

Abbott Laboratories [NYSE: ABT] stock went on an upward path that rose over 3.00% on Monday, amounting to a one-week price decrease of less than -0.48%. Over the last 12 months, ABT stock rose by 14.64%. The one-year Abbott Laboratories stock forecast points to a potential upside of 9.67. The average equity rating for ABT stock is currently 1.90, trading closer to a bullish pattern in the stock market.

The market cap for the stock reached $163.73 billion, with 1.77 billion shares outstanding and 1.76 billion shares in the current float. Compared to the average trading volume of 10.81M shares, ABT stock reached a trading volume of 5319999 in the most recent trading day, which is why market watchdogs consider the stock to be active.


>> Get free lesson

Get 12 free stock market lessons delivered to your email from Investor's Business Daily, the leader in investing education for over 35 years. We’ll cover the basics of better investing and show you how to give yourself an edge in the market.

GET FREE LESSON outside the norm.

Sponsored


Guru’s Opinion on Abbott Laboratories [ABT]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ABT shares is $102.47 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ABT stock is a recommendation set at 1.90. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Goldman have made an estimate for Abbott Laboratories shares, keeping their opinion on the stock as Sell, with their previous recommendation back on June 01, 2020. While these analysts kept the previous recommendation, Citigroup raised their target price to Buy. The new note on the price target was released on March 05, 2020, representing the official price target for Abbott Laboratories stock. Previously, the target price had yet another raise to $96, while Goldman analysts kept a Neutral rating on ABT stock.

The Average True Range (ATR) for Abbott Laboratories is set at 2.82, with the Price to Sales ratio for ABT stock in the period of the last 12 months amounting to 5.10. The Price to Book ratio for the last quarter was 5.42, with the Price to Cash per share for the same quarter was set at 2.07. Price to Free Cash Flow for ABT in the course of the last twelve months was 76.76 with Quick ratio for the last quarter at 1.00.

ABT Stock Performance Analysis:

Abbott Laboratories [ABT] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -0.48. With this latest performance, ABT shares dropped by -1.52% in over the last four-week period, additionally plugging by 8.59% over the last 6 months – not to mention a rise of 14.64% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ABT stock in for the last two-week period is set at 54.34, with the RSI for the last a single of trading hit 54.35, and the three-weeks RSI is set at 53.38 for Abbott Laboratories [ABT]. The present Moving Average for the last 50 days of trading for this stock 89.78, while it was recorded at 90.94 for the last single week of trading, and 85.26 for the last 200 days.

Insight into Abbott Laboratories Fundamentals:

Operating Margin for any stock indicates how profitable investing would be, and Abbott Laboratories [ABT] shares currently have an operating margin of +14.39 and a Gross Margin at +52.32. Abbott Laboratories’s Net Margin is presently recorded at +11.49.

Return on Total Capital for ABT is now 9.12, given the latest momentum, and Return on Invested Capital for the company is 7.45. Return on Equity for this stock inclined to 11.90, with Return on Assets sitting at 5.43. When it comes to the capital structure of this company, Abbott Laboratories [ABT] has a Total Debt to Total Equity ratio set at 61.44. Additionally, ABT Total Debt to Total Capital is recorded at 38.06, with Total Debt to Total Assets ending up at 28.13. Long-Term Debt to Equity for the company is recorded at 56.02, with the Long-Term Debt to Total Capital now at 34.70.

Reflecting on the efficiency of the workforce at the company, Abbott Laboratories [ABT] managed to generate an average of $34,262 per employee. Receivables Turnover for the company is 6.02 with a Total Asset Turnover recorded at a value of 0.47.Abbott Laboratories’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.00 and a Current Ratio set at 1.40.

ABT Stock EPS

With the latest financial reports released by the company, Abbott Laboratories posted 0.82/share EPS, while the average EPS was predicted by analysts to be reported at 0.8/share.When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 2.50%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ABT. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Abbott Laboratories go to 10.28%.

Abbott Laboratories [ABT] Insider Position Details

There are presently around $119,521 million, or 76.30% of ABT stock, in the hands of institutional investors. The top three institutional holders of ABT stocks are: VANGUARD GROUP INC with ownership of 155,793,753, which is approximately 2.642% of the company’s market cap and around 0.70% of the total institutional ownership; BLACKROCK INC., holding 128,123,947 shares of the stock with an approximate value of $11.51 billion in ABT stocks shares; and CAPITAL RESEARCH GLOBAL INVESTORS, currently with $8.61 billion in ABT stock with ownership of nearly -15.676% of the company’s market capitalization.

Positions in Abbott Laboratories stocks held by institutional investors increased at the end of April and at the time of the April reporting period, where 968 institutional holders increased their position in Abbott Laboratories [NYSE:ABT] by around 81,774,168 shares. Additionally, 1,062 investors decreased positions by around 86,614,018 shares, while 264 investors held positions by with 1,161,693,920 shares. The mentioned changes placed institutional holdings at 1,330,082,106 shares, according to the latest SEC report filing. ABT stock had 112 new institutional investments in for a total of 9,754,421 shares, while 141 institutional investors sold positions of 7,855,285 shares during the same period.

Get The Best Stocks To Trade Every Day!

Join now to get the DBTnews.com pre-market morning brief 100% free

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

Spirit Airline (SAVE), United Airline (UAL) Stock Surged, Quicker Recovery Will Be The Key To Growth

Good news on the efficacy of COVID-19 vaccines confirms stocks from airlines that have been among the most impacted by social activity constraints. Optimism...

NVIDIA (NVDA) Stock Lost After Q3 Results, Record Revenues Did Not Help

The graphics chip (GPU) manufacturer NVIDIA Corp. (NVDA) issued its report for the third quarter of the fiscal year 2021 after the close of...

U.S. Indices Started The Week Well, Oil Sector Also Gained

On the back of growing market operation and the results of testing another vaccine, our indexes rose Key-U.S. indices closed in the green zone on...

Unity Software (U) Stock Added 7% Last Week After Positive Quarterly Results

The stock of the game engine developer Unity Software Inc. (U) rose 5.58 percent on Friday to conclude the week at $122.80. An optimistic report...

Oil And Gold Drooped On Thursday, Markets Stimulates On Budget Support Plan

On Thursday, WTI oil dropped 0.2% to $41.74, while gold dropped 0.7% to $1,861.50 an ounce. Domestic oil inventories for the week ended November...

Get The Best Stocks To Trade Every Day!

Join now to get the DBTnews.com pre-market morning brief 100% free

Get The Best Stocks To Trade Every Day!

Join now to get the DBTNews.com pre-market morning brief 100% free

We do not sell or share your information with anyone.